Prophylactic Antibiotics to Prevent Cellulitis of the Leg: Economic Analysis of the PATCH I & II Trials
Open Access
- 14 February 2014
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (2) , e82694
Abstract
Cellulitis (erysipelas) is a recurring and debilitating bacterial infection of the skin and underlying tissue. We assessed the cost-effectiveness of prophylactic antibiotic treatment to prevent the recurrence of cellulitis using low dose penicillin V in patients following a first episode (6 months prophylaxis) and more recurrent cellulitis (12 months prophylaxis, or 6 months in those declining 12 months). Within-trial cost-effectiveness analysis was conducted using the findings of two randomised placebo-controlled multicentre trials (PATCH I and PATCH II), in which patients recruited in the UK and Ireland were followed-up for up to 3 years. Incremental cost, reduction in recurrence, cost per recurrence prevented and cost/QALY were estimated. National unit and reference costs for England in 2010 were applied to resource use, exploring NHS and societal perspectives. A total of 397 patients from the two trials contributed to the analysis. There was a 29% reduction in the number of recurrences occurring within the trial (IRR: 0.71 95%CI: 0.53 to 0.90, p = 0.02), corresponding to an absolute reduction of recurrence of 0.31 recurrences/patient (95%CI: 0.05 to 0.59, p = 0.02). Incremental costs of prophylaxis suggested a small cost saving but were not statistically significant, comparing the two groups. If a decision-maker is willing to pay up to £25,000/QALY then there is a 66% probability of antibiotic prophylaxis being cost-effective from an NHS perspective, rising to 76% probability from a secondary, societal perspective. Following first episode or recurrent cellulitis of the leg, prophylactic low dose penicillin is a very low cost intervention which, on balance, is effective and cost-effective at preventing subsequent attacks. Antibiotic prophylaxis reduces cellulitis recurrence by nearly a third but is not associated with a significant increase in costs.Keywords
This publication has 16 references indexed in Scilit:
- Prophylactic antibiotics for the prevention of cellulitis (erysipelas) of the leg: results of the U.K. Dermatology Clinical Trials Network’s PATCH II trialBritish Journal of Dermatology, 2011
- Severe lower limb cellulitis is best diagnosed by dermatologists and managed with shared care between primary and secondary careBritish Journal of Dermatology, 2011
- The Role of β-Hemolytic Streptococci in Causing Diffuse, Nonculturable CellulitisMedicine, 2010
- Lymphatic abnormalities demonstrated by lymphoscintigraphy after lower limb cellulitisBritish Journal of Dermatology, 2008
- Oedema as a risk factor for multiple episodes of cellulitis/erysipelas of the lower leg: a series with community follow-upBritish Journal of Dermatology, 2006
- Burden of illness of bacterial cellulitis and erysipelas of the leg in the NetherlandsJournal of the European Academy of Dermatology and Venereology, 2006
- Cost‐effectiveness acceptability curves – facts, fallacies and frequently asked questionsHealth Economics, 2004
- Analysis of cost data in randomized trials: an application of the non-parametric bootstrapStatistics in Medicine, 2000
- Antibiotic prophylaxis in recurrent erysipelasInfection, 1993
- Long-term antimicrobial therapy in the prevention of recurrent soft-tissue infectionsJournal of Infection, 1991